Potential and pitfalls of 1.5T MRI imaging for target volume definition in ocular proton therapy
•The potential and pitfalls of target volume definition in ocular proton therapy based on Magnetic Resonance Imaging (MRI) were investigated and compared to the conventional clinical method based on metallic clips implantation on 33 uveal melanoma patients.•In contrast to previous publications, an e...
Saved in:
Published in | Radiotherapy and oncology Vol. 154; pp. 53 - 59 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.01.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 0167-8140 1879-0887 1879-0887 |
DOI | 10.1016/j.radonc.2020.08.023 |
Cover
Loading…
Abstract | •The potential and pitfalls of target volume definition in ocular proton therapy based on Magnetic Resonance Imaging (MRI) were investigated and compared to the conventional clinical method based on metallic clips implantation on 33 uveal melanoma patients.•In contrast to previous publications, an extensive description of discrepancies between the different modeling of the target volumes, together with a thorough investigation of the causes, is performed, as well as an investigation into the potential dosimetric consequences.•For two out of thirty-three (6%) patients the lesion was invisible in MRI. Significant discrepancies between MRI and clips-based eye models were observed for tumor volume definition, with the MRI volumes being, on average, smaller than the clips-based one. Our results demonstrate that, independent of observer, while the height of MRI-based tumor volume agrees with the ultrasound assessment used in the conventional approach, inconsistencies in the definition of the base of the tumor between models produce the largest discrepancy in tumor volume definition.•We observed a decrease of delineation discrepancies between radiation oncologists as a function of tumor size suggesting that, the bigger the lesion, the more visible it is on MRI images.•Although the proposed MRI protocol has the potential to improve the accuracy of the eye model, on its own, it cannot replace the current clinical standard for target volume definition. However, the situation could change with the introduction of complementary ophthalmological imaging into the MRI approach in a geometrically accurate fashion.
Ocular proton therapy (OPT) for the treatment of uveal melanoma has a long and remarkably successful history. This is despite that, for the majority of patients treated, the definition of the eye anatomy is based on a simplified geometrical model embedded in the treatment planning system EyePlan. In this study, differences in anatomical and tumor structures from EyePlan, and those based on 1.5T magnetic resonance imaging (MRI) are assessed.
Thirty-three uveal melanoma patients treated with OPT at our institution were subject to eye MRI. The target volumes were manually delineated on those images by two radiation oncologists. The resulting volumes were geometrically compared to the clinical standard. In addition, the dosimetric impact of using different models for treatment planning were evaluated.
Two patients (6%) presented lesions too small to be visible on MRI. Target volumes identified on MRI scans were on average smaller than EyePlan with discrepancies arising mostly from the definition of the tumor base. Clip-to-tumor base distances measured on MRI models exhibited higher discrepancy to ophthalmological measurements than EyePlan. For 53% of cases, treatment plans optimized for lesions identified on MRI only, failed to achieve sufficient target coverage for EyePlan volumes.
The analysis has shown that 1.5T MRI might be more susceptible to misses of flat tumor extension of the clinical target volume than the current clinical standard. Thus, a proper integration of ancillary imaging modalities, leading to a better characterization of the full lesion, is required. |
---|---|
AbstractList | •The potential and pitfalls of target volume definition in ocular proton therapy based on Magnetic Resonance Imaging (MRI) were investigated and compared to the conventional clinical method based on metallic clips implantation on 33 uveal melanoma patients.•In contrast to previous publications, an extensive description of discrepancies between the different modeling of the target volumes, together with a thorough investigation of the causes, is performed, as well as an investigation into the potential dosimetric consequences.•For two out of thirty-three (6%) patients the lesion was invisible in MRI. Significant discrepancies between MRI and clips-based eye models were observed for tumor volume definition, with the MRI volumes being, on average, smaller than the clips-based one. Our results demonstrate that, independent of observer, while the height of MRI-based tumor volume agrees with the ultrasound assessment used in the conventional approach, inconsistencies in the definition of the base of the tumor between models produce the largest discrepancy in tumor volume definition.•We observed a decrease of delineation discrepancies between radiation oncologists as a function of tumor size suggesting that, the bigger the lesion, the more visible it is on MRI images.•Although the proposed MRI protocol has the potential to improve the accuracy of the eye model, on its own, it cannot replace the current clinical standard for target volume definition. However, the situation could change with the introduction of complementary ophthalmological imaging into the MRI approach in a geometrically accurate fashion.
Ocular proton therapy (OPT) for the treatment of uveal melanoma has a long and remarkably successful history. This is despite that, for the majority of patients treated, the definition of the eye anatomy is based on a simplified geometrical model embedded in the treatment planning system EyePlan. In this study, differences in anatomical and tumor structures from EyePlan, and those based on 1.5T magnetic resonance imaging (MRI) are assessed.
Thirty-three uveal melanoma patients treated with OPT at our institution were subject to eye MRI. The target volumes were manually delineated on those images by two radiation oncologists. The resulting volumes were geometrically compared to the clinical standard. In addition, the dosimetric impact of using different models for treatment planning were evaluated.
Two patients (6%) presented lesions too small to be visible on MRI. Target volumes identified on MRI scans were on average smaller than EyePlan with discrepancies arising mostly from the definition of the tumor base. Clip-to-tumor base distances measured on MRI models exhibited higher discrepancy to ophthalmological measurements than EyePlan. For 53% of cases, treatment plans optimized for lesions identified on MRI only, failed to achieve sufficient target coverage for EyePlan volumes.
The analysis has shown that 1.5T MRI might be more susceptible to misses of flat tumor extension of the clinical target volume than the current clinical standard. Thus, a proper integration of ancillary imaging modalities, leading to a better characterization of the full lesion, is required. Highlights•The potential and pitfalls of target volume definition in ocular proton therapy based on Magnetic Resonance Imaging (MRI) were investigated and compared to the conventional clinical method based on metallic clips implantation on 33 uveal melanoma patients. •In contrast to previous publications, an extensive description of discrepancies between the different modeling of the target volumes, together with a thorough investigation of the causes, is performed, as well as an investigation into the potential dosimetric consequences. •For two out of thirty-three (6%) patients the lesion was invisible in MRI. Significant discrepancies between MRI and clips-based eye models were observed for tumor volume definition, with the MRI volumes being, on average, smaller than the clips-based one. Our results demonstrate that, independent of observer, while the height of MRI-based tumor volume agrees with the ultrasound assessment used in the conventional approach, inconsistencies in the definition of the base of the tumor between models produce the largest discrepancy in tumor volume definition. •We observed a decrease of delineation discrepancies between radiation oncologists as a function of tumor size suggesting that, the bigger the lesion, the more visible it is on MRI images. •Although the proposed MRI protocol has the potential to improve the accuracy of the eye model, on its own, it cannot replace the current clinical standard for target volume definition. However, the situation could change with the introduction of complementary ophthalmological imaging into the MRI approach in a geometrically accurate fashion. Ocular proton therapy (OPT) for the treatment of uveal melanoma has a long and remarkably successful history. This is despite that, for the majority of patients treated, the definition of the eye anatomy is based on a simplified geometrical model embedded in the treatment planning system EyePlan. In this study, differences in anatomical and tumor structures from EyePlan, and those based on 1.5T magnetic resonance imaging (MRI) are assessed. Thirty-three uveal melanoma patients treated with OPT at our institution were subject to eye MRI. The target volumes were manually delineated on those images by two radiation oncologists. The resulting volumes were geometrically compared to the clinical standard. In addition, the dosimetric impact of using different models for treatment planning were evaluated. Two patients (6%) presented lesions too small to be visible on MRI. Target volumes identified on MRI scans were on average smaller than EyePlan with discrepancies arising mostly from the definition of the tumor base. Clip-to-tumor base distances measured on MRI models exhibited higher discrepancy to ophthalmological measurements than EyePlan. For 53% of cases, treatment plans optimized for lesions identified on MRI only, failed to achieve sufficient target coverage for EyePlan volumes. The analysis has shown that 1.5T MRI might be more susceptible to misses of flat tumor extension of the clinical target volume than the current clinical standard. Thus, a proper integration of ancillary imaging modalities, leading to a better characterization of the full lesion, is required. Ocular proton therapy (OPT) for the treatment of uveal melanoma has a long and remarkably successful history. This is despite that, for the majority of patients treated, the definition of the eye anatomy is based on a simplified geometrical model embedded in the treatment planning system EyePlan. In this study, differences in anatomical and tumor structures from EyePlan, and those based on 1.5T magnetic resonance imaging (MRI) are assessed.INTRODUCTIONOcular proton therapy (OPT) for the treatment of uveal melanoma has a long and remarkably successful history. This is despite that, for the majority of patients treated, the definition of the eye anatomy is based on a simplified geometrical model embedded in the treatment planning system EyePlan. In this study, differences in anatomical and tumor structures from EyePlan, and those based on 1.5T magnetic resonance imaging (MRI) are assessed.Thirty-three uveal melanoma patients treated with OPT at our institution were subject to eye MRI. The target volumes were manually delineated on those images by two radiation oncologists. The resulting volumes were geometrically compared to the clinical standard. In addition, the dosimetric impact of using different models for treatment planning were evaluated.MATERIALS AND METHODSThirty-three uveal melanoma patients treated with OPT at our institution were subject to eye MRI. The target volumes were manually delineated on those images by two radiation oncologists. The resulting volumes were geometrically compared to the clinical standard. In addition, the dosimetric impact of using different models for treatment planning were evaluated.Two patients (6%) presented lesions too small to be visible on MRI. Target volumes identified on MRI scans were on average smaller than EyePlan with discrepancies arising mostly from the definition of the tumor base. Clip-to-tumor base distances measured on MRI models exhibited higher discrepancy to ophthalmological measurements than EyePlan. For 53% of cases, treatment plans optimized for lesions identified on MRI only, failed to achieve sufficient target coverage for EyePlan volumes.RESULTSTwo patients (6%) presented lesions too small to be visible on MRI. Target volumes identified on MRI scans were on average smaller than EyePlan with discrepancies arising mostly from the definition of the tumor base. Clip-to-tumor base distances measured on MRI models exhibited higher discrepancy to ophthalmological measurements than EyePlan. For 53% of cases, treatment plans optimized for lesions identified on MRI only, failed to achieve sufficient target coverage for EyePlan volumes.The analysis has shown that 1.5T MRI might be more susceptible to misses of flat tumor extension of the clinical target volume than the current clinical standard. Thus, a proper integration of ancillary imaging modalities, leading to a better characterization of the full lesion, is required.DISCUSSIONThe analysis has shown that 1.5T MRI might be more susceptible to misses of flat tumor extension of the clinical target volume than the current clinical standard. Thus, a proper integration of ancillary imaging modalities, leading to a better characterization of the full lesion, is required. |
Author | Via, Riccardo Hennings, Fabian Fattori, Giovanni Beer, Jürgen Pica, Alessia Weber, Damien Charles Hrbacek, Jan Lomax, Antony Peroni, Marta Baroni, Guido |
Author_xml | – sequence: 1 givenname: Riccardo surname: Via fullname: Via, Riccardo email: riccardo.via@psi.ch organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 2 givenname: Fabian surname: Hennings fullname: Hennings, Fabian organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 3 givenname: Alessia surname: Pica fullname: Pica, Alessia organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 4 givenname: Giovanni surname: Fattori fullname: Fattori, Giovanni organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 5 givenname: Jürgen surname: Beer fullname: Beer, Jürgen organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 6 givenname: Marta surname: Peroni fullname: Peroni, Marta organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 7 givenname: Guido surname: Baroni fullname: Baroni, Guido organization: Dipartimento di Elettronica Informazione e Bioingegneria, Politecnico di Milano, Italy – sequence: 8 givenname: Antony surname: Lomax fullname: Lomax, Antony organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 9 givenname: Damien Charles surname: Weber fullname: Weber, Damien Charles organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland – sequence: 10 givenname: Jan surname: Hrbacek fullname: Hrbacek, Jan organization: Paul Scherrer Institut (PSI), Center for Proton Therapy, Switzerland |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32890606$$D View this record in MEDLINE/PubMed |
BookMark | eNqVkl9rFDEUxYNU7Hb1G4jk0ZeZJpk_yYgIUtQWKorW55hJ7qxZs8k2yRT225thqw-CFF8SCOecS373nKETHzwg9JySmhLan2_rqEzwumaEkZqImrDmEVpRwYeKCMFP0KrIeCVoS07RWUpbQoqy4U_QacPEQHrSr9D3zyGDz1Y5rLzBe5sn5VzCYcK07m7wxy9X2O7UxvoNnkLEWcUNZHwX3LwDbGCy3mYbPLYeBz07FfE-hlwe8g-Ian94ih6XxATP7u81-vb-3c3FZXX96cPVxdvrSne0z9VodA99q7U2RgAbW-iZpgMfoBPcKC2GjjXtOHbjyLVQhjdM6w66aer6kY-0WaOXx9wy_naGlOXOJg3OKQ9hTpK1LWl5w3tRpC_upfO4AyP3sfwwHuRvKkXQHgU6hpQiTH8klMgFvtzKI3y5wJdEyAK_2F79ZdM2q4VOjsq6h8xvjmYokO4sRJm0Ba_B2Ag6SxPs_wZoV5ajlfsJB0jbMEdfFiCpTEwS-XUpx9KNUgnCu3Ku0et_Bzw8_xcHcswG |
CitedBy_id | crossref_primary_10_1016_j_phro_2022_11_001 crossref_primary_10_1016_j_phro_2023_100517 crossref_primary_10_1088_1361_6560_ac0afb crossref_primary_10_1002_mp_17576 crossref_primary_10_3390_cancers15112995 crossref_primary_10_1007_s13246_024_01453_6 crossref_primary_10_1016_j_phro_2024_100598 crossref_primary_10_1016_j_radonc_2022_08_017 crossref_primary_10_1016_j_ijrobp_2024_06_017 crossref_primary_10_1016_j_oret_2022_06_019 crossref_primary_10_1016_j_radonc_2022_08_018 crossref_primary_10_1016_j_adro_2022_101149 crossref_primary_10_1016_j_radonc_2022_06_021 crossref_primary_10_1080_02713683_2021_1874021 crossref_primary_10_1016_j_radonc_2022_04_021 |
Cites_doi | 10.1088/0031-9155/46/3/304 10.1118/1.595258 10.1118/1.2068927 10.1007/s10334-016-0529-4 10.1016/j.ijrobp.2016.01.040 10.1007/s00066-006-1512-1 10.1016/j.ijrobp.2018.05.004 10.1016/j.ejmp.2015.03.009 10.1016/j.ijrobp.2018.02.008 10.1016/j.ijrobp.2015.02.056 10.1016/S0360-3016(01)01560-7 10.1002/mp.14087 10.1118/1.2168067 10.1016/S0360-3016(02)04200-1 10.3390/cancers11030377 10.1002/mrm.26534 10.1088/0031-9155/47/4/304 10.1088/1361-6560/aaf9c9 10.1118/1.3488891 |
ContentType | Journal Article |
Copyright | 2020 Elsevier B.V. Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.radonc.2020.08.023 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-0887 |
EndPage | 59 |
ExternalDocumentID | 32890606 10_1016_j_radonc_2020_08_023 S0167814020307520 1_s2_0_S0167814020307520 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 E3Z EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W J5H KOM M27 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SDG SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M Z5R ZGI ZXP ~G- 0SF AACTN AFCTW AFKWA AJOXV AMFUW RIG 6I. AAFTH AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR NCXOZ AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c516t-bdc6e64cccdd8e2b4e62c1979e587dac895234bb5bb7c8ad732cc5e5ff56b7b13 |
IEDL.DBID | .~1 |
ISSN | 0167-8140 1879-0887 |
IngestDate | Thu Jul 10 18:48:43 EDT 2025 Wed Feb 19 02:28:33 EST 2025 Thu Apr 24 23:07:38 EDT 2025 Tue Jul 01 01:41:10 EDT 2025 Fri Feb 23 02:47:17 EST 2024 Tue Feb 25 20:10:00 EST 2025 Tue Aug 26 16:34:35 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Uveal melanoma Ocular proton therapy Target volume definition Delineation uncertainties 1.5T magnetic resonance imaging |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2020 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c516t-bdc6e64cccdd8e2b4e62c1979e587dac895234bb5bb7c8ad732cc5e5ff56b7b13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0167814020307520 |
PMID | 32890606 |
PQID | 2440473768 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2440473768 pubmed_primary_32890606 crossref_primary_10_1016_j_radonc_2020_08_023 crossref_citationtrail_10_1016_j_radonc_2020_08_023 elsevier_sciencedirect_doi_10_1016_j_radonc_2020_08_023 elsevier_clinicalkeyesjournals_1_s2_0_S0167814020307520 elsevier_clinicalkey_doi_10_1016_j_radonc_2020_08_023 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-01-01 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland |
PublicationTitle | Radiotherapy and oncology |
PublicationTitleAlternate | Radiother Oncol |
PublicationYear | 2021 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Hrbacek, Mishra, Kacperek, Dendale, Nauraye, Auger (b0005) 2016; 95 Ciller, De Zanet, Rüegsegger, Pica, Sznitman, Thiran (b0095) 2015; 92 Oberacker, Paul, Huelnhagen, Oezerdem, Winter, Pohlmann (b0080) 2017; 78 Pfeiffer, Bendl (b0045) 2001; 46 Egger, Schalenbourg, Zografos, Bercher, Boehringer, Chamot (b0020) 2001; 51 Daftari, Aghaian, O'Brien, Dillon, Phillips (b0060) 2005; 32 Hennings, Lomax, Pica, Weber, Hrbacek (b0065) 2018 Egger, Zografos, Schalenbourg, Beati, Bhringer, Chamot (b0025) 2003; 55 Goitein, Miller (b0030) 1983; 10 Daftari, Mishra, O'Brien, Tsai, Park, Martin (b0070) 2010; 37 Nguyen, Sznitman, Maeder, Schalenbourg, Peroni, Hrbacek (b0100) 2018 Nurnberg, Riechardt, Zeitz, Heufelder, Joussen (b0040) 2018; 235 Kacperek (b0010) 2012 Marnitz, Cordini, Bendl, Lemke, Heufelder, Simiantonakis (b0015) 2006; 182 Rethfeldt, Fuchs, Gardey (b0050) 2006; 33 Via, Hennings, Fattori, Pica, Lomax, Weber (b0085) 2020; 47 Slopsema, Mamalui, Bolling, Flampouri, Yeung, Li (b0055) 2019; 64 Tsiapa, Tsilimbaris, Papadaki, Bouziotis, Pallikaris, Karantanas (b0075) 2015; 31 Dobler, Bendl (b0035) 2002; 47 Ferreira, Fonk, Jaarsma-Coes, van Haren, Marinkovic, Beenaker (b0090) 2019; 11 Beenakker, Ferreira, Soemarwoto, Genders, Teeuwisse, Webb (b0105) 2016; 29 Goitein (10.1016/j.radonc.2020.08.023_b0030) 1983; 10 Pfeiffer (10.1016/j.radonc.2020.08.023_b0045) 2001; 46 Via (10.1016/j.radonc.2020.08.023_b0085) 2020; 47 Tsiapa (10.1016/j.radonc.2020.08.023_b0075) 2015; 31 Kacperek (10.1016/j.radonc.2020.08.023_b0010) 2012 Slopsema (10.1016/j.radonc.2020.08.023_b0055) 2019; 64 Oberacker (10.1016/j.radonc.2020.08.023_b0080) 2017; 78 Ciller (10.1016/j.radonc.2020.08.023_b0095) 2015; 92 Egger (10.1016/j.radonc.2020.08.023_b0025) 2003; 55 Nguyen (10.1016/j.radonc.2020.08.023_b0100) 2018 Marnitz (10.1016/j.radonc.2020.08.023_b0015) 2006; 182 Egger (10.1016/j.radonc.2020.08.023_b0020) 2001; 51 Ferreira (10.1016/j.radonc.2020.08.023_b0090) 2019; 11 Daftari (10.1016/j.radonc.2020.08.023_b0060) 2005; 32 Daftari (10.1016/j.radonc.2020.08.023_b0070) 2010; 37 Dobler (10.1016/j.radonc.2020.08.023_b0035) 2002; 47 Hrbacek (10.1016/j.radonc.2020.08.023_b0005) 2016; 95 Nurnberg (10.1016/j.radonc.2020.08.023_b0040) 2018; 235 Hennings (10.1016/j.radonc.2020.08.023_b0065) 2018 Beenakker (10.1016/j.radonc.2020.08.023_b0105) 2016; 29 Rethfeldt (10.1016/j.radonc.2020.08.023_b0050) 2006; 33 |
References_xml | – volume: 95 start-page: 336 year: 2016 end-page: 343 ident: b0005 article-title: Practice pattern analysis of ocular proton therapy centers: The International OPTIC survey publication-title: Int J Radiat Oncol Biol Phys – volume: 51 start-page: 138 year: 2001 end-page: 147 ident: b0020 article-title: Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma publication-title: Int J Radiat Oncol Biol Phys – volume: 64 year: 2019 ident: b0055 article-title: Can CT imaging improve targeting accuracy in clip-based proton therapy of ocular melanoma publication-title: Phys Med Biol – year: 2018 ident: b0065 article-title: Automated treatment planning system for uveal melanomas treated with proton therapy: a proof for concept analysis publication-title: Int J Radiat Oncol Biol Phys – volume: 182 start-page: 395 year: 2006 end-page: 399 ident: b0015 article-title: Proton therapy of uveal melanomas publication-title: Strahlenther Onkol – volume: 32 start-page: 3355 year: 2005 end-page: 3362 ident: b0060 article-title: 3D MRI-based tumor delineation of ocular melanoma and its comparison with conventional techniques publication-title: Med Phys – volume: 235 start-page: 1001 year: 2018 end-page: 1012 ident: b0040 article-title: Multimodal imaging of the choroidal melanoma with differential diagnosis, therapy, radiation planning and follow-up publication-title: Kiln Monbl Augenheilkd – volume: 47 start-page: 2237 year: 2020 end-page: 2241 ident: b0085 article-title: Technical Note: Benchmarking automated eye tracking and human detection fro motion monitoring in ocular proton therapy publication-title: Med Phys – volume: 47 start-page: 593 year: 2002 end-page: 613 ident: b0035 article-title: Precise modelling of the eye for proton therapy of intra-ocular tumours publication-title: Phys Med Biol – volume: 55 start-page: 867 year: 2003 end-page: 880 ident: b0025 article-title: Eye retention after proton beam radiotherapy for uveal melanoma publication-title: Int J Radiat Oncol Biol Phys – volume: 33 start-page: 782 year: 2006 end-page: 791 ident: b0050 article-title: Dose distributions of a proton beam for eye tumor therapy: Hybrid pencil-beam and ray-tracing calculations publication-title: Med Phys – volume: 92 start-page: 794 year: 2015 end-page: 802 ident: b0095 article-title: Automatic segmentation of the eye in 3D magnetic resonance imaging: a novel statistical shape model for treatment planning of retinoblastoma publication-title: Int J Radiat Oncol Biol Phys – volume: 46 start-page: 671 year: 2001 end-page: 686 ident: b0045 article-title: Real-time dose calculation and visualization for the proton therapy of ocular tumours publication-title: Phys Med Biol – volume: 78 start-page: 1553 year: 2017 end-page: 1556 ident: b0080 article-title: Magnetic resonance safety and compatibility of tanatalum markers used in proton beam therapy for intraocular tumors: A 7.0 Tesla study publication-title: Magn Reson Med – volume: 37 start-page: 5199 year: 2010 end-page: 5207 ident: b0070 article-title: Fundus image fusion in EYEPLAN software: An evaluation of a novel technique for ocular melanoma radiation treatment planning publication-title: Med Phys – volume: 31 start-page: 774 year: 2015 end-page: 780 ident: b0075 article-title: High resolution MR eye protocol optimization: comparison between 3D-CISS, 3D-PSIF and 3D-VIBE sequences publication-title: Phys Med – year: 2018 ident: b0100 article-title: Personalized anatomic eye model from T1-weighted VIBE Mr imaging of patients with uveal melanoma publication-title: Int J Radiat Oncol Biol Phys – volume: 11 start-page: 377 year: 2019 ident: b0090 article-title: MRI of uveal melanoma publication-title: Cancers – volume: 29 start-page: 571 year: 2016 end-page: 577 ident: b0105 article-title: Clinical evaluation of ultra-high-field MRI for three-dimensional visualization of tumour size in uveal melanoma patinets with direct relevance to treatment planning publication-title: Magn Reson Mater Phys – volume: 10 start-page: 275 year: 1983 end-page: 283 ident: b0030 article-title: Planning proton therapy of the eye publication-title: Med Phys – start-page: 149 year: 2012 end-page: 177 ident: b0010 article-title: Ocular Proton Therapy Centers publication-title: Ion Beam Therapy – volume: 46 start-page: 671 year: 2001 ident: 10.1016/j.radonc.2020.08.023_b0045 article-title: Real-time dose calculation and visualization for the proton therapy of ocular tumours publication-title: Phys Med Biol doi: 10.1088/0031-9155/46/3/304 – volume: 10 start-page: 275 year: 1983 ident: 10.1016/j.radonc.2020.08.023_b0030 article-title: Planning proton therapy of the eye publication-title: Med Phys doi: 10.1118/1.595258 – volume: 32 start-page: 3355 year: 2005 ident: 10.1016/j.radonc.2020.08.023_b0060 article-title: 3D MRI-based tumor delineation of ocular melanoma and its comparison with conventional techniques publication-title: Med Phys doi: 10.1118/1.2068927 – volume: 29 start-page: 571 year: 2016 ident: 10.1016/j.radonc.2020.08.023_b0105 article-title: Clinical evaluation of ultra-high-field MRI for three-dimensional visualization of tumour size in uveal melanoma patinets with direct relevance to treatment planning publication-title: Magn Reson Mater Phys doi: 10.1007/s10334-016-0529-4 – start-page: 149 year: 2012 ident: 10.1016/j.radonc.2020.08.023_b0010 article-title: Ocular Proton Therapy Centers – volume: 95 start-page: 336 year: 2016 ident: 10.1016/j.radonc.2020.08.023_b0005 article-title: Practice pattern analysis of ocular proton therapy centers: The International OPTIC survey publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2016.01.040 – volume: 182 start-page: 395 year: 2006 ident: 10.1016/j.radonc.2020.08.023_b0015 article-title: Proton therapy of uveal melanomas publication-title: Strahlenther Onkol doi: 10.1007/s00066-006-1512-1 – year: 2018 ident: 10.1016/j.radonc.2020.08.023_b0100 article-title: Personalized anatomic eye model from T1-weighted VIBE Mr imaging of patients with uveal melanoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2018.05.004 – volume: 31 start-page: 774 year: 2015 ident: 10.1016/j.radonc.2020.08.023_b0075 article-title: High resolution MR eye protocol optimization: comparison between 3D-CISS, 3D-PSIF and 3D-VIBE sequences publication-title: Phys Med doi: 10.1016/j.ejmp.2015.03.009 – year: 2018 ident: 10.1016/j.radonc.2020.08.023_b0065 article-title: Automated treatment planning system for uveal melanomas treated with proton therapy: a proof for concept analysis publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2018.02.008 – volume: 92 start-page: 794 year: 2015 ident: 10.1016/j.radonc.2020.08.023_b0095 article-title: Automatic segmentation of the eye in 3D magnetic resonance imaging: a novel statistical shape model for treatment planning of retinoblastoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2015.02.056 – volume: 51 start-page: 138 year: 2001 ident: 10.1016/j.radonc.2020.08.023_b0020 article-title: Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(01)01560-7 – volume: 47 start-page: 2237 year: 2020 ident: 10.1016/j.radonc.2020.08.023_b0085 article-title: Technical Note: Benchmarking automated eye tracking and human detection fro motion monitoring in ocular proton therapy publication-title: Med Phys doi: 10.1002/mp.14087 – volume: 33 start-page: 782 year: 2006 ident: 10.1016/j.radonc.2020.08.023_b0050 article-title: Dose distributions of a proton beam for eye tumor therapy: Hybrid pencil-beam and ray-tracing calculations publication-title: Med Phys doi: 10.1118/1.2168067 – volume: 55 start-page: 867 year: 2003 ident: 10.1016/j.radonc.2020.08.023_b0025 article-title: Eye retention after proton beam radiotherapy for uveal melanoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(02)04200-1 – volume: 235 start-page: 1001 year: 2018 ident: 10.1016/j.radonc.2020.08.023_b0040 article-title: Multimodal imaging of the choroidal melanoma with differential diagnosis, therapy, radiation planning and follow-up publication-title: Kiln Monbl Augenheilkd – volume: 11 start-page: 377 year: 2019 ident: 10.1016/j.radonc.2020.08.023_b0090 article-title: MRI of uveal melanoma publication-title: Cancers doi: 10.3390/cancers11030377 – volume: 78 start-page: 1553 year: 2017 ident: 10.1016/j.radonc.2020.08.023_b0080 article-title: Magnetic resonance safety and compatibility of tanatalum markers used in proton beam therapy for intraocular tumors: A 7.0 Tesla study publication-title: Magn Reson Med doi: 10.1002/mrm.26534 – volume: 47 start-page: 593 year: 2002 ident: 10.1016/j.radonc.2020.08.023_b0035 article-title: Precise modelling of the eye for proton therapy of intra-ocular tumours publication-title: Phys Med Biol doi: 10.1088/0031-9155/47/4/304 – volume: 64 year: 2019 ident: 10.1016/j.radonc.2020.08.023_b0055 article-title: Can CT imaging improve targeting accuracy in clip-based proton therapy of ocular melanoma publication-title: Phys Med Biol doi: 10.1088/1361-6560/aaf9c9 – volume: 37 start-page: 5199 year: 2010 ident: 10.1016/j.radonc.2020.08.023_b0070 article-title: Fundus image fusion in EYEPLAN software: An evaluation of a novel technique for ocular melanoma radiation treatment planning publication-title: Med Phys doi: 10.1118/1.3488891 |
SSID | ssj0002037 |
Score | 2.4132464 |
Snippet | •The potential and pitfalls of target volume definition in ocular proton therapy based on Magnetic Resonance Imaging (MRI) were investigated and compared to... Highlights•The potential and pitfalls of target volume definition in ocular proton therapy based on Magnetic Resonance Imaging (MRI) were investigated and... Ocular proton therapy (OPT) for the treatment of uveal melanoma has a long and remarkably successful history. This is despite that, for the majority of... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 53 |
SubjectTerms | 1.5T magnetic resonance imaging Delineation uncertainties Hematology, Oncology, and Palliative Medicine Humans Magnetic Resonance Imaging Melanoma - diagnostic imaging Melanoma - radiotherapy Ocular proton therapy Proton Therapy Radiotherapy Planning, Computer-Assisted Target volume definition Uveal melanoma Uveal Neoplasms - diagnostic imaging Uveal Neoplasms - radiotherapy |
Title | Potential and pitfalls of 1.5T MRI imaging for target volume definition in ocular proton therapy |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0167814020307520 https://www.clinicalkey.es/playcontent/1-s2.0-S0167814020307520 https://dx.doi.org/10.1016/j.radonc.2020.08.023 https://www.ncbi.nlm.nih.gov/pubmed/32890606 https://www.proquest.com/docview/2440473768 |
Volume | 154 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS91AEF9EofRS1H5pVbbQa3zJfmTzjvJQnraKWAVv2_0KpLwmDxMPvfRv78wmUUsrSk-BzQxJZmdmZ7O_mSHkEy_zorBcJAwWs0QEPk2MEDYB4oKnRmGUi2iLs3x-JU6u5fUKmY25MAirHHx_79Ojtx5GJoM0J8uqmnxFAD3Wa2Kop5Lhvl0IhVq-_-se5gF31VjfG6nH9LmI8boxvqmxkCFLYyFPxh9bnh4LP-MydLROXg3xIz3oX3GDrIR6k7w4HU7IX5Nv502HACCgMbWny6orzWLR0qak2b68pKcXx7T6EVsTUYhXaY8Ep72Toj6UVR1BXLSqaRMxqhRLOcBAn6n18w25Ojq8nM2ToYtC4mSWd4n1Lg-5cM55XwRmRciZy6ZqGmShvHHFFPaiwlpprXKF8Yoz52SQZSlzq2zG35LVuqnDe0LTzGD4kwoLQUHGYP6DwkZ4noGtlZZvET4KT7uhxDh2uljoEUv2Xfci1yhyjQ0wGXAld1zLvsTGE_RynBc9po-Cw9OwBjzBp_7FF9rBalud6ZbpVP-lWQ85_1DOZzzz46g4GuwWD2NMHZrbVjMszKjAvRdb5F2vUXdfz_H0F3aW2__93A_kJUPwTfxXtENWu5vbsAvRU2f3onnskbWD2cWXc7wef56f_QbRAxlZ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZhA20vpe-mTxV6ddfWw_IeQ2jYbbJLaTeQm6qXwWFrL7FzyL_PjC0vLW1I6VXMIFueGY2sb74h5CMv86KwXCQMNrNEBD5LjBA2AeGCp0Zhlotoi1U-PxNfzuX5Hjkaa2EQVhlj_xDT-2gdR6ZxNafbqpp-RwA98jUxtFPJ4Ny-j-xUckL2Dxcn89UuIIOAGim-UWGsoOthXpfGNzVyGbK05_Jk_LYd6rYMtN-Jjh-RhzGFpIfDUz4me6F-Qu4t4yX5U_Lja9MhBghkTO3ptupKs9m0tClp9kmu6fLbglY_--5EFFJWOoDB6RCnqA9lVfc4LlrVtOlhqhTZHGBgKNa6fkbOjj-vj-ZJbKSQOJnlXWK9y0MunHPeF4FZEXLmspmaBVkob1wxg-OosFZaq1xhvOLMORlkWcrcKpvx52RSN3V4SWiaGcyAUmEhL8gYmEBQ2AvPM3C30vIDwsfF0y6yjGOzi40e4WQXelhyjUuusQcmA61kp7UdWDbukJfjd9FjBSnEPA3bwB166m96oY2O2-pMt0yn-g_j-lXzN_v8hzk_jIajwXXxPsbUoblqNUNuRgURvjggLwaL2r09xwtgOFy--u9535P78_XyVJ8uVievyQOGWJz-19EbMukur8JbSKY6-y46yw2VoRp1 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Potential+and+pitfalls+of+1.5T+MRI+imaging+for+target+volume+definition+in+ocular+proton+therapy&rft.jtitle=Radiotherapy+and+oncology&rft.au=Via%2C+Riccardo&rft.au=Hennings%2C+Fabian&rft.au=Pica%2C+Alessia&rft.au=Fattori%2C+Giovanni&rft.date=2021-01-01&rft.issn=0167-8140&rft.volume=154&rft.spage=53&rft.epage=59&rft_id=info:doi/10.1016%2Fj.radonc.2020.08.023&rft.externalDBID=ECK1-s2.0-S0167814020307520&rft.externalDocID=1_s2_0_S0167814020307520 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01678140%2Fcov200h.gif |